Our experience
Нour specialists have considerable experience in all common nosologies, and also have special competence in conducting research of early phases. Use the filter to select the categories of research and services you are interested in.
Services
Year
INN | Code | АТС | Services | Year |
---|---|---|---|---|
Teriflunomide | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2021 |
Sorafenib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2021 |
Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bringing dossier into the EEU complience | 2021 |
Bortezomib | L01XX | Ингибиторы протеинкиназы | Bringing dossier into the EEU complience | 2021 |
Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Bringing dossier into the EEU complience | 2021 |
Darunavir | J05AE | HIV-proteinase inhibitors | Bringing dossier into the EEU complience | 2021 |
Metronidazole | A01AB | Antiinfectives For Local Oral Treatment | Bringing dossier into the EEU complience | Present |
Oxaliplatin | L01XA | Platinum Compounds | Bringing dossier into the EEU complience | Present |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2021 |
Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2021 |
Interferon y | L03AB | Interferons | Phase III CT | Present |
Сlindamycin + Adapalene | D01A | Antifungals for topical use | Bringing dossier into the EEU complience | 2021 |
Ketoconazole + Pyrithione zinc | D01A | Antifungals for topical use | Bringing dossier into the EEU complience | 2021 |
Desloratadine | R06AX | Other Antihistamines for systemic use | Marketing Authorization | Present |
Tibolone | G03CX | Other estrogens | Marketing Authorization | Present |
Acetylcysteine | R05CB | Mucolytics | Marketing Authorization | Present |
Decitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | Present |
Glucoseminyl muramildipeptide | L03AX | Other Immunostimulating Agents | Bringing dossier into the EEU complience | 2021 |
Imipenem + Cilastatin | J01DH | Carbapenems | Marketing Authorization | Present |
Atosiban | G02CX | Gynecologicals, other | Marketing Authorization | Present |
Iloprost | B01AC | Platelet Aggregation Inhibitors Excl. | Marketing Authorization | Present |
Nimodipine | C08CA | Dihydropyridine Derivatives | Marketing Authorization | Present |
Aminoacids for parenteral nutrition | A16AA | Amino Acids and Derivatives | Marketing Authorization | Present |
Dexmedetomidine | N05C | Hypnotics and Sedatives | Marketing Authorization | Present |
Teriflunomide | L04AA | Selective Immunosuppressive Agents | Marketing Authorization | Present |
Nitisinone | A16AX | Various Alimentary Tract and Metabolism Products | Marketing Authorization | Present |
Biapenem | J01D | Third-generation cephalosporins | Marketing Authorization | Present |
Paclitaxel | L01CD | Taxanes | Marketing Authorization | Present |
Сolistimethate sodium | J01XB | Polymyxins | Marketing Authorization | Present |
Cinacalcet | H05BX | Other anti-parathyroid agents | Marketing Authorization | Present |
Gadodiamide | V08CA | Paramagnetic Contrast Media | Marketing Authorization | Present |
Dantrolene | M03CA | Dantrolene and Derivatives | Marketing Authorization | Present |
Cefuroxime | J01RA | Combinations Of Antibacterials | Marketing Authorization | Present |
Ertapenem | J01DH | Carbapenems | Marketing Authorization | Present |
Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Marketing Authorization | Present |
Vancomycin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | Present |
Tiepenem | J01DH | Carbapenems | Marketing Authorization | Present |
Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | Present |
Aminoacids for parenteral nutrition | A16AA | Amino Acids and Derivatives | Marketing Authorization | Present |
Clotrimazole | D01AC | Imidazole Derivatives | Bringing dossier into the EEU complience | 2021 |
Adapalenum + Clindamycinum | D10AD | Retinoids for topical use In Acne | Bringing dossier into the EEU complience | 2021 |
Combined herb drug | A01AD | Other Agents For Local Oral Treatment | Bioequivalence CT | 2021 |
Hydrochlorothiazidum + Telmisartan | C09DA | Angiotensin II Antagonists and Diuretics | Bioequivalence CT | 2021 |
Indapamid + Perindopril + Rosuvastatin | C10BX | HMG CoA reductase inhibitors, other combinations | Bioequivalence CT | 2021 |
Dabigatrani etexilas | B01AA | Vitamin K Antagonists | Bioequivalence CT | Present |
Amlodipinum + Indapamidum + Perindoprilum | C09BX | Ингибиторы АПФ, другие комбинации | Bioequivalence CT | 2021 |
Apixaban | B01AF | Other Antithrombotic Agents | Bioequivalence CT | Present |
Dapagliflozin | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | Bioequivalence CT | Present |
Tilorone | J05AX | Other Antivirals | Bioequivalence CT | Present |
Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2021 |
Etravirin | J05AG | Ненуклеозиды - ингибиторы обратной транскриптазы | Bioequivalence CT | 2021 |
Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2021 |
Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2021 |
Posaconazole | J02AC | Triazole Derivatives | Bioequivalence CT | 2021 |
Teriflunomide | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2021 |
Etravirin | J05AG | Ненуклеозиды - ингибиторы обратной транскриптазы | Bioequivalence CT | 2020 |
Cinacalcet | H05BX | Other anti-parathyroid agents | Bioequivalence CT | 2020 |
Sunitinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2020 |
Nitisinone | A16AX | Various Alimentary Tract and Metabolism Products | Bioequivalence CT | 2020 |
Nilotinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2020 |
Lenalidomide | L04AX | Other Immunosuppressive Agents | Bioequivalence CT | 2020 |
Desloratadine | R06AX | Other Antihistamines for systemic use | Bioequivalence CT | 2020 |
Dasatinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2020 |
Acetylcysteine | R05CB | Mucolytics | Bioequivalence CT | 2020 |
Gefitinib | L01XX | Other Antineoplastic Agents | Bioequivalence CT | 2020 |
Chlorprothixen | N05AF | Thioxanthene Derivatives | Bioequivalence CT | 2020 |
Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2020 |
Vinorelbine | L01CA | Vinca alkaloids and analogues | Marketing Authorization | 2020 |
Melatonin + Glycine | N06BX | Other Psychostimulants and Nootropics | Phase III CT | 2020 |
Rabeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2020 |
Trimebutine | A03AA | Synt Anticholin,Esters With Tertiary Amino Group | Bioequivalence CT | 2020 |
Tolperisone | M02AX | Other Topical Products For Joint and Muscular Pain | Bioequivalence CT | 2020 |
Mebeverine | A03AA | Synt Anticholin,Esters With Tertiary Amino Group | Bioequivalence CT | 2020 |
Cefoperazone | J01DD | Third-generation cephalosporins | Marketing Authorization | 2020 |
Cefoxitin | J01DC | Second-generation cephalosporins | Marketing Authorization | 2020 |
Ketoanalogues of aminoacids | V06DD | Amino Acids, Incl Combinations With Polypeptides | Marketing Authorization | 2020 |
Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Marketing Authorization | 2020 |
Oseltamyvir | J05AH | Neuraminidase inhibitors | Bringing dossier into the EEU complience | 2020 |
Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2020 |
Paracetamol + Phenylephrine + Pheniramine + Caffeine | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2020 |
Saquinavir | J05AE | HIV-proteinase inhibitors | Marketing Authorization | 2020 |
Ademetionin | A16AA | Amino Acids and Derivatives | Marketing Authorization | 2020 |
Ambroxol + Salbutamol + Guaifenesin | R05C | Expectorants,Excl Combinations With Cough Suppr. | Marketing Authorization | 2020 |
Amoxicillin + Sulbactam | J01CG | Beta-Lactamase Inhibitors | Marketing Authorization | 2020 |
Ampicillin + Sulbactam | J01CR | Comb Of Penicillins, Incl. Beta-Lactamase Inhib. | Marketing Authorization | 2020 |
Amylmetacresol + Dichlorobenzyl alcohol | R02AA | Antiseptics | Marketing Authorization | 2020 |
Anagrelide | L01XX | Other Antineoplastic Agents | Marketing Authorization | 2020 |
Aripiprazole | N05AX | Other Antipsychotics | Bioequivalence CT | 2020 |
Aripiprazole | N05AX | Other Antipsychotics | Marketing Authorization | 2020 |
Aztreonam | J01DF | Monobactams | Marketing Authorization | 2020 |
Caffeine + Paracetamol + Phenylephrine + Chlorphenamine | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2020 |
Cefepime | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2020 |
Cefoperazone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2020 |
Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2020 |
Vildagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | Bioequivalence CT | 2020 |
Vildagliptin + Metformin | A10BD | Biguanides and Sulfonamides In Combination | Bioequivalence CT | 2020 |
Clotrimazole | D01A | Antifungals for topical use | Marketing Authorization | 2020 |
Cyproterone | G03HA | Antiandrogens, Plain Preparations | Marketing Authorization | 2020 |
Cytisine | N07BA | Antismoking Agents | Marketing Authorization | 2020 |
Dexmedetomidine | N05CM | Other Hypnotics and Sedatives | Marketing Authorization | 2020 |
Dimetinden | R06A | Antihistamines for systemic use | Marketing Authorization | 2020 |
Diosmin + Hesperidin | C05CA | Bioflavonoids | Marketing Authorization | 2020 |
Docetaxel | L01CD | Taxanes | Marketing Authorization | 2020 |
Domperidone | A03FA | Propulsives | Marketing Authorization | 2020 |
Desogestrel + Ethinylestradiol | G03AA | Progestogens and Estrogens, Fixed Combinations | Bioequivalence CT | 2020 |
Donepezil | N06DA | Cholinesterase inhibitors | Bioequivalence CT | 2020 |
Fluvoxamine | N06AB | Serotonin Reuptake Inhibitors Selective | Marketing Authorization | 2020 |
Fosfomycin | J01XX | Other Antibacterials | Marketing Authorization | 2020 |
Gemcitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | 2020 |
Ibuprofen | M01AE | Propionic Acid Derivatives | Marketing Authorization | 2020 |
Ibuprofen + Paracetamol | M01AE | Propionic Acid Derivatives | Marketing Authorization | 2020 |
Iodixanol | V08A | X-Ray Contrast Media, Iodinated | Marketing Authorization | 2020 |
Irinotecan | L01XX | Ингибиторы протеинкиназы | Marketing Authorization | 2020 |
Josamycin | J01FA | Macrolides | Marketing Authorization | 2020 |
Lysocime + Pyridoxine | R02AA | Antiseptics | Marketing Authorization | 2020 |
Metronidazole + Chlorhexidine | A01AB | Antiinfectives For Local Oral Treatment | Marketing Authorization | 2020 |
Montelukast | R03DC | Leukotriene receptor antagonists | Marketing Authorization | 2020 |
Naftifine | D01A | Antifungals for topical use | Marketing Authorization | 2020 |
Natamycin | A07AA | Antibiotics | Marketing Authorization | 2020 |
Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Marketing Authorization | 2020 |
Olmesartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2020 |
Omeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2020 |
Ornidazole | J01XD | Imidazole Derivatives | Marketing Authorization | 2020 |
Ornidazole + Ciprofloxacin | J01RA | Combinations Of Antibacterials | Marketing Authorization | 2020 |
Pancreatin | A09AA | Enzyme Preparations | Marketing Authorization | 2020 |
Phosphazide | J05AF | Nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2020 |
Telmisartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2020 |
Tigecycline | J01AA | Tetracyclines | Marketing Authorization | 2020 |
Trastuzumab | L01XC | Monoclonal antibodies | Marketing Authorization | 2020 |
Adalimumab | L04AB | Tumor necrosis factor alpha (TNF alpha;) inhibitors | Phase III CT | 2020 |
Donepezil | N06DA | Cholinesterase inhibitors | Bioequivalence CT | 2020 |
Abiraterone | L02BX | Other hormone antagonists and related agents | Marketing Authorization | 2019 |
Amlodipine | C08CA | Dihydropyridine Derivatives | Marketing Authorization | 2019 |
Amlodipine | C08CA | Dihydropyridine Derivatives | Рharmacovigilance | Present |
Atracurium besylate | M03AC | Other Quaternary Ammonium Compounds | Рharmacovigilance | Present |
Bleomycin | L01DC | Other Cytotoxic Antibiotics | Marketing Authorization | 2019 |
Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Marketing Authorization | 2019 |
Carbamazepine | N03AF | Carboxamide Derivatives | Рharmacovigilance | Present |
Carboplatin | L01XA | Platinum Compounds | Marketing Authorization | 2019 |
Celecoxib | M01AH | Coxibs | Рharmacovigilance | Present |
Cisplatin | L01XA | Platinum Compounds | Рharmacovigilance | Present |
Cyclophosphamide | L01AA | Nitrogen Mustard Analogues | Marketing Authorization | 2019 |
Docetaxel | L01CD | Taxanes | Рharmacovigilance | Present |
Docetaxel | L01CD | Taxanes | Marketing Authorization | 2019 |
Donepezil | N06DA | Cholinesterase inhibitors | Marketing Authorization | 2019 |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Рharmacovigilance | Present |
Enoxaparin | B01AB | Heparin Group | Marketing Authorization | 2019 |
Epirubicin | L01DB | Anthracyclines and Related Substances | Рharmacovigilance | Present |
Ferric (III) hydroxide sacharose complex | B03AC | Iron, Parenteral Preparations | Рharmacovigilance | Present |
Gemcitabine | L01BC | Pyrimidine Analogues | Рharmacovigilance | Present |
Imipenem + Cilastatin | J01DH | Carbapenems | Рharmacovigilance | Present |
Isoniazid | J04AC | Hydrazides | Рharmacovigilance | Present |
Loratadine | R06AX | Other Antihistamines for systemic use | Рharmacovigilance | Present |
Meropenem | J01DH | Carbapenems | Marketing Authorization | 2019 |
Moxifloxacin | J01MA | Fluoroquinolones | Рharmacovigilance | Present |
Original drug | G01BA | Antibiotics and Corticosteroids | Phase III CT | 2019 |
Original drug | G01BA | Antibiotics and Corticosteroids | Marketing Authorization | 2019 |
Original drug | J05AX | Other Antivirals | Marketing Authorization | 2019 |
Ornidazole | J01XD | Imidazole Derivatives | Рharmacovigilance | Present |
Paracetamol | N02B | Other Analgesics and Antipyretics | Рharmacovigilance | Present |
Pregabalin | N03AX | Other Antiepileptics | Рharmacovigilance | Present |
Pyrazinamide | J04AK | Other Drugs For Treatment Of Tuberculosis | Рharmacovigilance | Present |
Temozolomide | L01AX | Other Alkylating Agents | Рharmacovigilance | Present |
Acetylcysteine + Ambroxol | R05CB | Mucolytics | Phase III CT | 2019 |
Agomelatine | N06AX | Other Antidepressants | Bioequivalence CT | 2019 |
Ambroxol + Salbutamol + Guaifenesin | R05C | Expectorants,Excl Combinations With Cough Suppr. | Phase III CT | 2019 |
Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | Phase III CT | 2019 |
Ethylmethylhydroxypyridine succinate | N07XX | Other Nervous System Drugs | Phase III CT | 2019 |
Olmesartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2019 |
Lysocime + Pyridoxine | R02AA | Antiseptics | Phase III CT | 2019 |
Pregabalin | N03AX | Other Antiepileptics | Bioequivalence CT | 2019 |
Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | Bioequivalence CT | 2019 |
Telmisartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2019 |
Ursodeoxycholic acid | A05AA | Bile Acid Preparations | Bioequivalence CT | 2019 |
Chlormadinone + Ethinyl Estradiol | G03AA | Progestogens and Estrogens, Fixed Combinations | Bioequivalence CT | 2019 |
Ketolorac | M01AB | Acetic Acid Derivatives and Related Substances | Phase III CT | 2019 |
Hydrocortisone acetate + Metronidazole + Natamycin + Chloramphenicol | G01BA | Antibiotics and Corticosteroids | Phase III CT | 2019 |
Abacavir + Lamivudine + Zidovudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2016-2018 |
Amoxicillin + Clavulanic acid | A07EC | Aminosalicylic Acid and Similar Agents | Marketing Authorization | 2016-2018 |
Atazanavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
Atazanavir | J05AE | HIV-proteinase inhibitors | Marketing Authorization | 2016-2018 |
Bendamustine | L01AA | Nitrogen Mustard Analogues | Marketing Authorization | 2016-2018 |
Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2016-2018 |
Ceftriaxone | J01DD | Third-generation cephalosporins | Marketing Authorization | 2016-2018 |
Chlorambucil | L01AA | Nitrogen Mustard Analogues | Marketing Authorization | 2016-2018 |
Ciprofloxacin | J01MA | Fluoroquinolones | PVG | Present |
Cisplatin | L01XA | Platinum Compounds | Marketing Authorization | 2016-2018 |
Dasatinib | L01XE | Ингибиторы протеинкиназы | Marketing Authorization | 2016-2018 |
Doripenem | J01DH | Carbapenems | Marketing Authorization | 2016-2018 |
Doxorubicin | L01DB | Anthracyclines and Related Substances | Marketing Authorization | 2016-2018 |
Etoposide | L01CB | Podophyllotoxin Derivatives | Marketing Authorization | 2016-2018 |
Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2016-2018 |
Etoricoxib | M01AH | Coxibs | Marketing Authorization | 2016-2018 |
Fingolimod | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2016-2018 |
Fluorouracil | L01BC | Pyrimidine Analogues | Marketing Authorization | 2016-2018 |
Flutamide | L02BB | Anti-Androgens | Marketing Authorization | 2016-2018 |
Ganciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2016-2018 |
Hydroxycarbamide | L01XX | Other Antineoplastic Agents | Marketing Authorization | 2016-2018 |
Ibrutinib | L01XE | Ингибиторы протеинкиназы | Bioequivalence CT | 2016-2018 |
Ketorolac trometamol | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Phase III CT | 2016-2018 |
Lapatinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
Lenalidomide | L04AX | Other Immunosuppressive Agents | Marketing Authorization | 2016-2018 |
Methotrexate | L01BA | Folic Acid Analogues | Marketing Authorization | 2016-2018 |
Metronidazole | J01XD | Imidazole Derivatives | PVG | Present |
Nifuroxazide | A07AX | Other Intestinal Antiinfectives | Marketing Authorization | 2016-2018 |
Nilotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | 2016-2018 |
Original drug | B01AC | Platelet Aggregation Inhibitors Excl. | Marketing Authorization | 2016-2018 |
Pantoprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2016-2018 |
Pazopanib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
Saquinavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
Sofosbuvir | J05AP | Antivirals for treatment of HCV infections | Bioequivalence CT | 2016-2018 |
Tamoxifen | L02BA | Anti-Estrogens | Marketing Authorization | 2016-2018 |
Telmisartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2016-2018 |
Abacavir + Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Marketing Authorization | 2016-2018 |
Abiraterone | L02BX | Other hormone antagonists and related agents | Bioequivalence CT | 2016-2018 |
Abiraterone | L02BX | Other hormone antagonists and related agents | Marketing Authorization | 2016-2018 |
Albendazole | P02CA | Benzimidazole Derivatives | Bioequivalence CT | 2016-2018 |
Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2016-2018 |
Bosentan | C02KX | Antihypertensives for pulmonary arterial hypertension | Bioequivalence CT | 2016-2018 |
Capecitabine | L01BC | Pyrimidine Analogues | Bioequivalence CT | 2016-2018 |
Celecoxib | M01AH | Coxibs | Bioequivalence CT | 2016-2018 |
Cisplatin | L01XA | Platinum Compounds | Marketing Authorization | 2016-2018 |
Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Marketing Authorization | 2016-2018 |
Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Bioequivalence CT | 2016-2018 |
Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2016-2018 |
Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
Diclofenac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | PVG | Present |
Dorzolamide | S01EC | Carbonic Anhydrase Inhibitors | Marketing Authorization | 2016-2018 |
Entecavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2016-2018 |
Esomeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2016-2018 |
Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2016-2018 |
Etoricoxib | M01AH | Coxibs | Marketing Authorization | 2016-2018 |
Ferric (III) hydroxide sacharose complex | B03AC | Iron, Parenteral Preparations | Marketing Authorization | 2016-2018 |
Gefitinib | L01XX | Other Antineoplastic Agents | Bioequivalence CT | 2016-2018 |
Iohexol | V08AB | Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media | Marketing Authorization | 2016-2018 |
Lamivudine | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2016-2018 |
Meloxicam | M01AC | Oxicams | Marketing Authorization | 2016-2018 |
Montelukast | R03DC | Leukotriene receptor antagonists | Marketing Authorization | 2016-2018 |
Mycophenolic acid | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2016-2018 |
Nitrofurantoin | J01XE | Nitrofuran derivatives | Marketing Authorization | 2016-2018 |
Ofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2016-2018 |
Original drug | J01DD | Third-generation cephalosporins | Marketing Authorization | 2016-2018 |
Paracetamol + Phenylephrine + Chlorphenamine maleate | N02B | Other Analgesics and Antipyretics | Bioequivalence CT | 2016-2018 |
Quetiapine | N05AH | Diazepines and oxazepines | Bioequivalence CT | 2016-2018 |
Ritonavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | Marketing Authorization | 2016-2018 |
Solifenacin | G04BD | Urinary Antispasmodics | Bioequivalence CT | 2016-2018 |
Sorafenib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2016-2018 |
Torasemide | C03CA | Sulfonamides, Plain | Marketing Authorization | 2016-2018 |
Tranexamic acid | B02AA | Amino Acids | Marketing Authorization | 2016-2018 |
Cefepime | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2016-2018 |
Cinacalcet | H05BX | Other anti-parathyroid agents | Marketing Authorization | 2016-2018 |
Docetaxel | L01CD | Taxanes | Phase III CT | 2016-2018 |
Efavirenz + Emtricitabine + Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2016-2018 |
Entecavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2016-2018 |
Imatinib | L01XE | Ингибиторы протеинкиназы | Marketing Authorization | 2016-2018 |
Imatinib | L01XE | Ингибиторы протеинкиназы | Bioequivalence CT | 2016-2018 |
Irbesartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2016-2018 |
Lenalidomide | L04AX | Other Immunosuppressive Agents | Bioequivalence CT | 2016-2018 |
Levocetirizine | R06AE | Piperazine Derivatives | Marketing Authorization | 2016-2018 |
Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2016-2018 |
Levofloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2016-2018 |
Linezolid | J01XX | Other Antibacterials | Marketing Authorization | 2016-2018 |
Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2016-2018 |
Nilotinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
Original drug | B01AC | Platelet Aggregation Inhibitors Excl. | Phase III CT | 2016-2018 |
Original drug | J01DD | Third-generation cephalosporins | Phase III CT | 2016-2018 |
Oseltamivir | J05AH | Combinations Of Antibacterials | Bioequivalence CT | 2016-2018 |
Peginterferon alfa-2b | L03AB | Interferons | Marketing Authorization | 2016-2018 |
Pregabalin | N03AX | Other Antiepileptics | Marketing Authorization | 2016-2018 |
Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | Bioequivalence CT | 2016-2018 |
Sildenafil | G04BE | Drugs used in erectile dysfunction | Marketing Authorization | 2016-2018 |
Sildenafil | G04BE | Drugs used in erectile dysfunction | Bioequivalence CT | 2016-2018 |
Sunitinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
Tacrolimus | L04AD | Calcineurin inhibitors | Marketing Authorization | 2016-2018 |
Temozolomide | L01AX | Other Alkylating Agents | Bioequivalence CT | 2016-2018 |
Tenofovir + Emtricitabine | J05AR | Antivirals for treatment of HIV infections, combination | Marketing Authorization | 2016-2018 |
Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2016-2018 |
Tramadol | N02AX | Other Opioids | Marketing Authorization | 2016-2018 |
Valganciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2016-2018 |
Vancomycin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | 2016-2018 |
Abacavir + Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Bioequivalence CT | 2013-2015 |
Amoxicillin + Clavulanic acid | A07EC | Aminosalicylic Acid and Similar Agents | Bioequivalence CT | 2013-2015 |
Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Phase III CT | 2013-2015 |
Celecoxib | M01AH | Coxibs | Bioequivalence CT | 2013-2015 |
Cinacalcet | H05BX | Other anti-parathyroid agents | Bioequivalence CT | 2013-2015 |
Ciprofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
Dienogest + Ethinylestradiol | G03FA | Progestogens and Estrogens, Fixed Combinations | Bioequivalence CT | 2013-2015 |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
Efavirenz + Emtricitabine + Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
Erlotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | 2013-2015 |
Erlotinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2013-2015 |
Famciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2013-2015 |
Irbesartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2013-2015 |
Ivabradine | C01EB | Other Cardiac Preparations | Marketing Authorization | 2013-2015 |
Ivabradine | C01EB | Other Cardiac Preparations | Bioequivalence CT | 2013-2015 |
Latanoprost | S01EE | Prostaglandin analogues | Phase III CT | 2013-2015 |
Levofloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2013-2015 |
Linezolid | J01XX | Other Antibacterials | Marketing Authorization | 2013-2015 |
Linezolid | J01XX | Other Antibacterials | Bioequivalence CT | 2013-2015 |
Linezolid | J01XX | Other Antibacterials | Phase III CT | 2013-2015 |
Losartan + Hydrochlorothiazide | C09DA | Angiotensin II Antagonists and Diuretics | Marketing Authorization | 2013-2015 |
Meropenem | J01DH | Carbapenems | Marketing Authorization | 2013-2015 |
Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
Nevirapine | J05AG | Non-nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
Pimecrolimus | D11AH | Agents for atopic dermatitis, excluding corticosteroids | Phase III CT | 2013-2015 |
Pregabalin | N03AX | Other Antiepileptics | Bioequivalence CT | 2013-2015 |
Rabeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2013-2015 |
Rabeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2013-2015 |
Stavudine | J05AF | Nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
Tenofovir + Emtricitabine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
Terizidone + Pyridoxine | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2013-2015 |
Timolol | S01ED | Beta Blocking Agents | Marketing Authorization | 2013-2015 |
Topiramate | N03AX | Other Antiepileptics | Marketing Authorization | 2013-2015 |
Travoprost | S01EE | Prostaglandin analogues | Phase III CT | 2013-2015 |
Valaciclovir | J05AB | Nucleosides and nucleotides | Bioequivalence CT | 2013-2015 |
Valganciclovir | J05AB | Nucleosides and nucleotides | Bioequivalence CT | 2013-2015 |
Valsartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2013-2015 |
Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2013-2015 |
Atracurium besilate | M03AC | Other Quaternary Ammonium Compounds | Marketing Authorization | 2013-2015 |
Darunavir | J05AE | HIV-proteinase inhibitors | Marketing Authorization | 2013-2015 |
Docetaxel | L01CD | Taxanes | Marketing Authorization | 2013-2015 |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
Famciclovir | J05AB | Nucleosides and nucleotides | Bioequivalence CT | 2013-2015 |
Imatinib | L01XE | Ингибиторы протеинкиназы | Marketing Authorization | 2013-2015 |
Imipenem + Cilastatin | J01DH | Carbapenems | Marketing Authorization | 2013-2015 |
Lamivudine + Zidovudine | J05AR | Antivirals for treatment of HIV infections, combination | Marketing Authorization | 2013-2015 |
Levocetirizine | R06AE | Piperazine Derivatives | Bioequivalence CT | 2013-2015 |
Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
Menotropins | G03GA | Gonadotrophins | Marketing Authorization | 2013-2015 |
Meropenem | J01DH | Carbapenems | Marketing Authorization | 2013-2015 |
Mesalazine | A07EC | Aminosalicylic Acid and Similar Agents | Marketing Authorization | 2013-2015 |
Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
Moxifloxacin | J01MA | Fluoroquinolones | Phase III CT | 2013-2015 |
Natural phospholipids | R07AA | Lung Surfactants | Marketing Authorization | 2013-2015 |
Ofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
Paracetamol | N02B | Other Analgesics and Antipyretics | Phase III CT | 2013-2015 |
Peginterferon | L03AB | Interferons | Phase III CT | 2013-2015 |
Rabeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2013-2015 |
Sulodexide | B01AB | Heparin Group | Phase III CT | 2013-2015 |
Teicoplanin | J01XA | Glycopeptide Antibacterials | Phase III CT | 2013-2015 |
Terizidone + Pyridoxine | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
Tobramycin | J01GB | Other Aminoglycosides | Phase III CT | 2013-2015 |
Torasemide | C03CA | Sulfonamides, Plain | Bioequivalence CT | 2013-2015 |
Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2013-2015 |
Citalopram | N06AB | Serotonin Reuptake Inhibitors Selective | Marketing Authorization | 2013-2015 |
Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Marketing Authorization | 2013-2015 |
Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
Cycloserine + Pyridoxine | J04A | Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
Cyproterone + Ethinylestradiol | G03HB | Antiandrogens and Estrogens | Marketing Authorization | 2013-2015 |
Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2013-2015 |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
Gabapentin | N03AX | Other Antiepileptics | Marketing Authorization | 2013-2015 |
Heparin | B01AB | Heparin Group | Marketing Authorization | 2013-2015 |
Ketorolac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Marketing Authorization | 2013-2015 |
Lamivudine | J05AF | Nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
Lamivudine | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
Levofloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2013-2015 |
Moxifloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2013-2015 |
Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Marketing Authorization | 2013-2015 |
Sildenafil | G04BE | Drugs used in erectile dysfunction | Bioequivalence CT | 2013-2015 |
Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2013-2015 |
Topiramate | N03AX | Other Antiepileptics | Marketing Authorization | 2013-2015 |
Urofollitropin | G03GA | Gonadotrophins | Marketing Authorization | 2013-2015 |
Zidovudine + Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
Anastrozole | L02BG | Enzyme Inhibitors | Marketing Authorization | 2010-2012 |
Bisoprolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
Clarithromycin | J01FA | Macrolides | Marketing Authorization | 2010-2012 |
Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E | M09AX | Other Drugs For Disord. Of The Musc.-Skeletal Syst | Marketing Authorization | 2010-2012 |
Isoniazid + Pyrazinamide + Rifampicin | J04AM | Comb. Of Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2010-2012 |
Letrozole | L02BG | Enzyme Inhibitors | Marketing Authorization | 2010-2012 |
Levetiracetam | N03AX | Other Antiepileptics | Marketing Authorization | 2010-2012 |
Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
Mycophenolate mofetil | L04AA | Selective Immunosuppressive Agents | Marketing Authorization | 2010-2012 |
Nebivolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
Paracetamol | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2010-2012 |
Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Marketing Authorization | 2010-2012 |
Rebamipide | A02BX | Other Drugs For Treatment Of Peptic Ulcer | Marketing Authorization | 2010-2012 |
Tacrolimus | L04AD | Calcineurin inhibitors | Marketing Authorization | 2010-2012 |
Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2010-2012 |
Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2010-2012 |
Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2010-2012 |
Amoxicillin + Clavulanic acid | A07EC | Aminosalicylic Acid and Similar Agents | Marketing Authorization | 2010-2012 |
Bisoprolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
Capreomycin | J04AB | Antibiotics | Marketing Authorization | 2010-2012 |
Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2010-2012 |
Diclofenac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Marketing Authorization | 2010-2012 |
Drotaverine | A03AD | Papaverine and Derivatives | Marketing Authorization | 2010-2012 |
Epirubicin | L01DB | Anthracyclines and Related Substances | Marketing Authorization | 2010-2012 |
Hydrochlorothiazide + Losartan | C09DA | Angiotensin II Antagonists and Diuretics | Marketing Authorization | 2010-2012 |
Indapamide | C03BA | Sulfonamides, Plain | Marketing Authorization | 2010-2012 |
Ketorolac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Marketing Authorization | 2010-2012 |
Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
Meropenem | J01DH | Carbapenems | Marketing Authorization | 2010-2012 |
Metamizole sodium + Pitofenone + Fenpiverinium bromide | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2010-2012 |
Nebivolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
Ornidazole | J01XD | Imidazole Derivatives | Marketing Authorization | 2010-2012 |
Rabeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2010-2012 |
Gemcitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | 2010-2012 |
Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
Temozolomide | L01AX | Other Alkylating Agents | Marketing Authorization | 2010-2012 |
Alglucosidase alfa | A16AB | Enzymes | User testing of leaflet | 2020 |
Bortezomib | L01XX | Other Antineoplastic Agents | User testing of leaflet | 2020 |
Oxaliplatin | L01XA | Platinum Compounds | User testing of leaflet | 2020 |
Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | User testing of leaflet | 2020 |
Levonorgestrel | G03AC | 3-Oxoandrosten (4) Derivatives | User testing of leaflet | 2020 |
Cyproterone | G03HA | Antiandrogens, Plain Preparations | User testing of leaflet | 2020 |
Darunavir | J05AE | HIV-proteinase inhibitors | User testing of leaflet | 2020 |
Mycophenolic acid | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2021 |
Cyproterone | G03HA | Antiandrogens, Plain Preparations | User testing of leaflet | 2020 |
Decitabine | L01BC | Pyrimidine Analogues | User testing of leaflet | 2020 |
Mycophenolate mofetil | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2020 |
Insulin glargine + Lixisenatide | A10AE | Insulins and analogues, long-acting | User testing of leaflet | 2020 |
Darunavir | J05AE | HIV-proteinase inhibitors | User testing of leaflet | 2020 |
Aceclofenac | M01AB | Acetic Acid Derivatives and Related Substances | User testing of leaflet | 2020 |
Hydrochlorothiazidum + Telmisartan | C09DA | Angiotensin II Antagonists and Diuretics | User testing of leaflet | 2020 |
Lenalidomide | L04AX | Other Immunosuppressive Agents | User testing of leaflet | 2020 |
Etoricoxib | M01AH | Coxibs | User testing of leaflet | 2020 |
Telmisartan + Amlodipin | C09DB | Антагонисты ангиотензина II в комбинации с блокаторами кальциевых каналов | User testing of leaflet | 2020 |
Rosuvastatin + Valsartan | C10BX | HMG CoA reductase inhibitors, other combinations | User testing of leaflet | 2020 |
Drugs for treatment of hyperkalemia and hyperphosphatemia | V03AE | Drugs for treatment of hyperkalemia and hyperphosphatemia | User testing of leaflet | 2021 |
Influenza Vaccines | J07B | Influenza Vaccines | User testing of leaflet | 2021 |
Doxylamine | R06AA | Aminoalkyl Ethers | User testing of leaflet | 2021 |
Telmisartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2021 |
Poliomyelitis Vaccines | J07BF | Poliomyelitis Vaccines | User testing of leaflet | 2021 |
Algeldrate | A02A | Antacids | User testing of leaflet | 2021 |
Fulvestrant | L02BA | Anti-Estrogens | User testing of leaflet | 2021 |
Carvedilol | C07AG | Alpha and Beta Blocking Agents | User testing of leaflet | 2021 |
Nifedipine | C08CA | Dihydropyridine Derivatives | User testing of leaflet | 2021 |
Azithromycin | J01FA | Macrolides | User testing of leaflet | 2021 |
Azithromycin | J01FA | Macrolides | User testing of leaflet | 2021 |
Ciprofloxacin | J01MA | Fluoroquinolones | User testing of leaflet | 2021 |
Lenvatinib | L01XE | Ингибиторы протеинкиназы | User testing of leaflet | 2021 |
Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | User testing of leaflet | 2021 |
Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | User testing of leaflet | 2021 |
Desloratadine | R06AX | Other Antihistamines for systemic use | User testing of leaflet | 2021 |
immunoglobulin | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2021 |
Amiodarone | C01BD | Antiarrhythmics, Class III | User testing of leaflet | 2021 |
Valproic acid | N03AG | Fatty Acid Derivatives | User testing of leaflet | 2021 |
Poliomyelitis Vaccines | J07BF | Poliomyelitis Vaccines | User testing of leaflet | 2021 |
Sorafenib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2021 |
Vardenafil | G04BE | Drugs used in erectile dysfunction | User testing of leaflet | 2021 |
Telmisartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2021 |
Regorafenib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2021 |
Telmisartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2021 |
Cemiplimab | L01XC | Monoclonal antibodies | User testing of leaflet | 2021 |
Vericiguat | C01DA | Organic nitrates | User testing of leaflet | 2021 |
Metronidazole | J01XD | Imidazole Derivatives | User testing of leaflet | 2021 |
Lenalidomide | L04AX | Other Immunosuppressive Agents | User testing of leaflet | 2021 |
Combined herb drug | A01AD | Other Agents For Local Oral Treatment | User testing of leaflet | 2021 |
Ibuprofen | M01AE | Propionic Acid Derivatives | User testing of leaflet | 2021 |
Alectinib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2021 |
Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | User testing of leaflet | 2021 |
Dabigatrani etexilas | B01AA | Vitamin K Antagonists | User testing of leaflet | 2021 |
Dabigatrani etexilas | B01AA | Vitamin K Antagonists | User testing of leaflet | 2021 |
Faricimab | L01XC | Monoclonal antibodies | User testing of leaflet | 2021 |
Finerenone | С03AA | Thiazide diuretics | User testing of leaflet | 2021 |
Aducanumab | N06DX | Other anti-dementia drugs | User testing of leaflet | 2021 |
Amlodipine | C08CA | Dihydropyridine Derivatives | User testing of leaflet | 2021 |
Alirocumab | C10AX | Other Cholesterol and Triglyceride Reducers | User testing of leaflet | 2021 |
Glycopyrronii bromidum + Indacaterolum | H02AB | Glucocorticoids | User testing of leaflet | 2021 |
Agalsidase Alfa | A16AB | Enzymes | User testing of leaflet | 2021 |
Other Viral Vaccines | J07BX | Other Viral Vaccines | User testing of leaflet | 2021 |
Сitric acid + Potassium bicarbonate + Sodium citrate | G04BC | Urinary Concrement Solvents | User testing of leaflet | 2021 |
Benzyldimethyl-myristoilamin-propylammonium | D08AJ | Quaternary Ammonium Compounds | User testing of leaflet | 2021 |
Insulin glargine | A10AE | Insulins and analogues, long-acting | User testing of leaflet | 2021 |
Ivacaftor | R07AX | Other Respiratory System Products | User testing of leaflet | 2021 |
Clotrimazole | D01A | Antifungals for topical use | User testing of leaflet | 2021 |
Abiraterone | L02BX | Other hormone antagonists and related agents | User testing of leaflet | 2021 |
Sildenafil | G04BE | Drugs used in erectile dysfunction | User testing of leaflet | 2021 |
Vemurafenib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2021 |
Thyme | R05CA | Expectorants | User testing of leaflet | 2021 |
Salmeterol + Fluticasone | R03AK | Sympathomimetics in combination with corticosteroids or other drugs, excluding anticholinergics | User testing of leaflet | 2021 |
Salbutamol sulfate | R05CB | Mucolytics | User testing of leaflet | 2021 |
Metronidazole | J01XD | Imidazole Derivatives | User testing of leaflet | 2021 |
Thiamine + Aescine | C05CX | Other Capillary Stabilizing Agents | User testing of leaflet | 2021 |
Ticagrelor | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | User testing of leaflet | 2021 |
Levodopa | N04BA | Dopa and dopa derivatives | User testing of leaflet | 2021 |
Adalimumab | L04AB | Tumor necrosis factor alpha (TNF alpha;) inhibitors | User testing of leaflet | 2021 |
Dapagliflozin | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | User testing of leaflet | 2021 |
Hederae folium | R05CA | Expectorants | User testing of leaflet | 2021 |
Salmeterol + Fluticasone | R03AK | Sympathomimetics in combination with corticosteroids or other drugs, excluding anticholinergics | User testing of leaflet | Present |
Sitagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | User testing of leaflet | Present |
Perampanel | N03A | Other Antiepileptics | User testing of leaflet | Present |
Glycopyrronii bromidum | H02AB | Glucocorticoids | User testing of leaflet | 2022 |
Baloxavir marboxil | J05AX | Other Antivirals | User testing of leaflet | Present |
Plerixafor | L03AX | Other Immunostimulating Agents | User testing of leaflet | Present |
Herbal drug | R07AX | Other Respiratory System Products | User testing of leaflet | Present |
Cobimetinib | L01XE | Protein kinase inhibitors | User testing of leaflet | Present |
Herbal drug | A03AX | Other Synthetic Anticholinergic Agents | User testing of leaflet | Present |
Polyvitamine | A11BA | Multivitamins, Plain | Bringing dossier into the EEU complience | Present |
Erlotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | Present |
Paliperidone | N05AX | Other Antipsychotics | Marketing Authorization | Present |
Mometasone | D07AC | Corticosteroids, Potent (Group III) | Marketing Authorization | Present |
Diclofenac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Bringing dossier into the EEU complience | Present |
Amylmetacresol + Dichlorobenzyl alcohol | R02AA | Antiseptics | Bringing dossier into the EEU complience | Present |
Ademetionin | A16AA | Amino Acids and Derivatives | Marketing Authorization | Present |
Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Marketing Authorization | Present |
Cabazitaxel | L01CD | Taxanes | Marketing Authorization | Present |
Cefoperazone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | Present |
Rivaroxaban | B01AF | Direct factor Xa inhibitors | Bioequivalence CT | Present |
Lapatinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | Present |
Telmisartan + Amlodipin | C09DB | Антагонисты ангиотензина II в комбинации с блокаторами кальциевых каналов | Bioequivalence CT | Present |
Rivaroxaban | B01AF | Direct factor Xa inhibitors | Bioequivalence CT | Present |
Raltegravir | J05AX | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | Present |
Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | Present |
Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | Present |
CONTACTS
Russia, Moscow.
Multifanctional complex «Federation»
Presnenskaya embankment, 12
East Tower, 27th floor, 17 room.
Phone: + 7 (495) 374-62-84
E-mail: info@pharmrussia.com
Social network:
© ARS PHARMRUSSIA: CLINICAL & REGULATORY EXPERT CRO, 2009-2020
All rights reserved.